When to hold Direct Oral Anticoagulants (DOACs) preoperatively?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Timing of DOAC Discontinuation Before Surgery

For patients on direct oral anticoagulants (DOACs), discontinuation should occur 1 day before low bleeding risk procedures and 2 days before high bleeding risk procedures, with additional time needed for patients with impaired renal function. 1

DOAC Discontinuation Timeline by Bleeding Risk

Low Bleeding Risk Procedures:

  • Apixaban: Hold for 1 day (CrCl >25 mL/min)
  • Dabigatran: Hold for 1 day (CrCl >50 mL/min) or 2 days (CrCl 30-50 mL/min)
  • Edoxaban: Hold for 1 day (CrCl >15 mL/min)
  • Rivaroxaban: Hold for 1 day (CrCl >30 mL/min)

High Bleeding Risk Procedures:

  • Apixaban: Hold for 2 days (CrCl >25 mL/min)
  • Dabigatran: Hold for 2 days (CrCl >50 mL/min) or 4 days (CrCl 30-50 mL/min)
  • Edoxaban: Hold for 2 days (CrCl >15 mL/min)
  • Rivaroxaban: Hold for 2 days (CrCl >30 mL/min)

Special Considerations

Renal Function

  • For patients with CrCl lower than the values in the table, consider holding for an additional 1-3 days, especially for high bleeding risk procedures 1
  • For dabigatran (which has significant renal elimination):
    • Hold for 4 days if CrCl >50 mL/min for high-risk procedures
    • Hold for 5 days if CrCl is between 30-50 mL/min for high-risk procedures 1

Very High Bleeding Risk Procedures

For procedures with very high bleeding risk (e.g., intracranial neurosurgery or neuraxial anesthesia/puncture):

  • Consider longer interruption times (up to 5 days) for all DOACs in the absence of renal failure 1
  • Specific DOAC level testing may be considered if available, though not routinely required 2

Urgent/Emergent Procedures

For urgent procedures (within 24 hours):

  • Consider laboratory testing to measure DOAC levels if time permits 3
  • DOAC levels above 50 ng/mL may be considered clinically relevant and may necessitate reversal agents before urgent procedures 2
  • In life-threatening situations, don't wait for DOAC level results before initiating reversal 2

Bridging Anticoagulation

  • Preoperative bridging with heparin (UFH or LMWH) is not recommended when interrupting DOACs 1, 4
  • No bridging therapy is needed unless the patient has very high thrombotic risk (e.g., recent history of pulmonary embolism or deep venous thrombosis) 4

DOAC Resumption After Surgery

  • For low bleeding risk procedures: Resume DOACs at least 6 hours after the procedure 1

    • For once-daily evening regimen: Resume the evening of the procedure day
    • For once-daily morning regimen: Resume the next morning
    • For twice-daily regimen: Resume the evening of the same day
  • For high bleeding risk procedures: Delay resumption for 48-72 hours 4, 3

    • Consider starting with prophylactic doses of LMWH 6-12 hours after surgery if hemostasis is adequate and there's concern about thrombotic risk 4

Common Pitfalls to Avoid

  1. Unnecessary bridging: Bridging with heparin is generally not needed and may increase bleeding risk without reducing thrombotic risk 1, 4
  2. One-size-fits-all approach: Failing to adjust timing based on renal function can lead to excessive anticoagulant effect during surgery
  3. Inadequate discontinuation time: Not allowing sufficient time for drug clearance before high bleeding risk procedures
  4. Premature resumption: Restarting DOACs too early after high bleeding risk procedures can increase bleeding complications
  5. Delayed resumption: Waiting too long to restart anticoagulation increases thrombotic risk

By following these evidence-based guidelines for DOAC management before surgery, you can minimize both bleeding and thrombotic complications in your patients.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Peri-Procedural Management of Anticoagulants for Colonoscopy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.